Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer

Purpose The neurokinin-1 receptor antagonist, casopitant, is a weak-to-moderate inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A) and has the potential to inhibit the metabolism of CYP3A substrates such as docetaxel. Methods Fourteen cancer patients were enrolled in this phase 1, open-label, random...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2011-04, Vol.67 (4), p.783-790
Hauptverfasser:	Dandamudi, Uday B., Adams, Laurel M., Johnson, Brendan, Bauman, John, Morris, Shannon, Murray, Sharon, Webb, R. Timothy, Gartner, Elaina, Hohl, Raymond, Lewis, Lionel D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antiemetics - adverse effects Antiemetics - pharmacology Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Area Under Curve Biological and medical sciences Cancer Research Cross-Over Studies Cytochrome P-450 CYP3A Cytochrome P-450 CYP3A Inhibitors Dexamethasone - pharmacology Docetaxel Drug Therapy, Combination Enzyme Inhibitors - pharmacology Female Humans Least-Squares Analysis Leukocyte Count Male Medical sciences Medicine Medicine & Public Health Middle Aged Neoplasms - drug therapy Neurokinin-1 Receptor Antagonists Neutrophils - metabolism Oncology Ondansetron - pharmacology Original Article Pharmacology. Drug treatments Pharmacology/Toxicology Piperazines - adverse effects Piperazines - pharmacology Piperidines - adverse effects Piperidines - pharmacology Taxoids - adverse effects Taxoids - pharmacokinetics Taxoids - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!